February 22, 2019
As the Advance/Decline Line (A/DL) exhibited Thursday with a minor gap with 21/22 and 1 flat)
Warmer climates (86) do make the cold (39) go far away – it’s my “bones” that were suffering
News: Voyager Therapeutics (VYGR) and AbbVie (ABBV), a global biopharmaceutical company, today announced an exclusive, global strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson’s disease and other diseases (synucleinopathies) characterized by the abnormal accumulation of misfolded alpha-synuclein protein.
Quarterly results: bluebird Bio Inc. (BLUE) on Thursday reported a Q4 loss of $149 or -$2.72 per share beat “street” expectations for a loss of $2.83 per share. BioMarin Pharmaceutical (BMRN) reported a Q4 loss of $3.7 M or -$0.03 per share. Losses, adjusted for one-time gains and costs, were -$0.06 per share. The results missed “street” expectations for earnings of $0.10 per share.
Pre-open indications: 3 BUY, 1 SELL and 1 TRADE
February 11, 2019
Q4/18 financial results is a scorecard of (AKA) earnings of 45 covered companies
3 out of 45 ...The current LPS (loss per share) or net income, cash positions i.e. "runways" and correlation of "street" expectations - it's a reflection of this universe's investing "status"
Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
February 20, 2019
As quarterly forecasts are not meeting anticipation
Volatility is heightened as “street” expectations are taking a “kitchen insinkerator” churn
Pre-open indications: 3 HITs and 2 MISS (1 by pennies)
Earnings: Mesoblast (MESO) reports Q2 net loss of -$24.6 M or -$5.00 per share and 1st half “numbers - $77 M in cash ($15 M of debt financing), revenue of $13.5 M, an R&D increase of $2.4 M and SG&A with a $5.1 M financing cost
It’s not hard to be right so often; that’s why the term “quantamental,” a blend of the two styles, may soon become common parlance among investors and traders.
February 11, 2019
Q4/18 financial results is a scorecard of (AKA) earnings of 45 covered companies 3 out of 45 ... The current LPS (loss per share) or net income, cash positions i.e. "runways" and correlation of "street" expectations - it's a reflection of this universe's investing "status" Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
January 23, 2019
The opening was about the “feeling” of the oversold but, the reliance of trust versus conviction pushes the session … The Advance/Decline Line has deteriorated ... Yet the “bottoms” are being bought! There’s a difference between trust and conviction. Trust is something you can rely on, beyond certainty. Conviction doesn't demand that you, or anyone else, play by the rules. After gains, there’s pain; followed by advances, declines and other progressions or was it regressions? Confidence perceived is not always value achieved!
January 22, 2019
EDIT (-$4.48 or -17.13%), Intellia Therapeutics (NTLA -$1.05 or -6.88%) and CRISPR Therapeutics (CRSP -$4.07 or -10.96%) equities plunged EDIT volume is HIGH with 3.7 M shares traded <3 month average = 792.8 K shares, CRSP volume is also HIGH with 1.79 M shares traded <3 month average = 834.7 K shares> and NTLA volume is as LOWER with 577.05 K shares traded <3 month average = 694.3 K shares>
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
February 22, 2019
RegMed Investors’ (RMi) pre-open: transcending to a Friday close
February 21, 2019
RegMed Investors’ (RMi) pre-open: before investors kept swept away with pricing panics
February 20, 2019
RegMed Investors’ (RMi) closing bell: risk is acerbated by a down turning sector
February 20, 2019
RegMed Investors’ (RMi) pre-open: the cracks in the sector
© 2019 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
